A recent study shows a bio-marker based blood test can accurately distinguish epilepsy seizures from psychogenic non-epileptic seizures (PNES).
The study was from Cognizance Biomarkers, a subsidiary of Evogen Inc. The preliminary evidence was presented at the 2018 Annual Meeting of the American Epilepsy Society (AES).
PNES are common and account for around 20% or more of patients seeking treatment for epilepsy. They are hard to distinguish from epileptic seizures and are related to psychological factors rather than electrical disturbances in the brain.
The blood test is simple to administer and aims to accurately diagnose epilepsy seizures based on the patented methods for biomarker assessment, leveraging recent research showing the neuro-inflammation is associated with epilepsy and is both a cause and consequence of seizures. Previous clinical studies have confirmed the ability of the biomarker test to distinguish actual seizures from seizure-like events.